Close Menu

La Jolla Institute for Allergy and Immunology

A new partnership and licensing agreement will help the research institute aggregate genotype and phenotype data for the NIH-funded PreCISE Network asthma program.

The researchers hope the datasets from their study can help to explain the effects of disease-associated variants on specific cell types of the immune system.

A La Jolla Institute for Allergy and Immunology-led team sequenced the transcriptomes of thousands of CD4+ T cells and compared their expression patterns.

The Human Immunome Program, which is part of the Human Vaccines Project, eventually plans to profile B-cell and T-cell receptors in more than 1,000 individuals.

The La Jolla Institute for Allergy and Immunology (LIAI) has joined the Sanford Consortium for Regenerative Medicine, a new facility in San Diego that is set to open in November and will focus on stem cell research.

LIAI is preparing to assemble a permanent staff to run the screening facility, which is expected to include a manager and two full-time technicians, as well as a center director.

If MedImmune can develop and market a drug based on the discovery, it could be a financial boost to the institute, which hopes to diversify its revenue sources once cash from sole corporate sponsor Kirin Pharma USA dries up in 2010.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.